Nautilus (NAUT) Q2 FY26 earnings call

Nautilus is strategically realigning its R&D resources, shifting focus and investment from its broad-scale proteome application to proteoform development due to strong customer demand and technical momentum. While the broad-scale application faces delays, the company is accelerating its proteoform roadmap, aiming for commercialization with instrument pre-orders in early 2027. Management is prudently managing cash and plans future fundraising to support this expanded proteoform strategy.